Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : COVID-19 Approved In Pakistan For People Under 40

06/16/2021 | 01:30am EDT


© MT Newswires 2021
All news about ASTRAZENECA PLC
02:40pPFIZER : Brazil reopens amid looming threat from delta variant
AQ
02:10pRelaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
AQ
01:55pCORONAVIRUS – TUNISIA : Belgium sends emergency aid to Tunisia in the figh..
AQ
08:28aASTRAZENECA : Secures FDA Approval for Bydureon BCise Injectable Suspension for ..
MT
06:26aAstraZeneca's Bydureon BCise Gets U.S. Approval For Type 2 Diabetes in Pediat..
DJ
05:06aCORRECTION : AstraZeneca Says Data Shows One Dose of COVID-19 Jab 'Highly Effect..
MT
04:48aASTRAZENECA : Single-Dose COVID-19 Jab Shows Effect Against Beta, Gamma, Delta V..
MT
04:43aAstraZeneca's Covid-19 Vaccine Effective Against Variants After One Dose, Can..
DJ
04:31aT&T GROUP : Le gouvernement vietnamien soutient T&T Group pour l'achat de 40 mil..
DJ
04:08aASTRAZENECA : Vaxzevria is highly effective after one dose against severe diseas..
PU
More news
Financials (USD)
Sales 2021 31 752 M - -
Net income 2021 4 669 M - -
Net Debt 2021 10 816 M - -
P/E ratio 2021 24,0x
Yield 2021 3,32%
Capitalization 131 B 181 B -
EV / Sales 2021 4,48x
EV / Sales 2022 3,88x
Nbr of Employees 76 100
Free-Float 81,1%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 84,80 $
Average target price 132,19 $
Spread / Average Target 55,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.50%155 197
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
ELI LILLY AND COMPANY41.25%209 276
NOVARTIS AG0.20%207 246